A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Trial Profile

A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms MAPS2
  • Most Recent Events

    • 19 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 According to a Bristol-Myers Squibb media release, data from the study will be presented at the 2017 American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top